ABBV FDA calendar & decision history AbbVie · 1 upcoming · 13 past FDA decisions
Upcoming FDA catalysts ABBV · Dec 31, 2026 Tavapadon (TEMPO) — Early Parkinson's disease FDA decision history (13) Jun 26, 2026✓ Approved SKYRIZI (risankizumab-rzaa) Jun 16, 2026✓ Approved JUVÉDERM - (SKINVIVE) (injecta May 27, 2026✓ Approved LINZESS (Iinaclotide) Apr 23, 2026✕ CRL trenibotulinumtoxinE (Trenibot Feb 20, 2026✓ Approved FDA decision Nov 18, 2025✓ Approved FDA decision Oct 13, 2025✓ Approved FDA decision Jun 30, 2025✓ Approved FDA decision Jun 11, 2025✓ Approved FDA decision May 14, 2025✓ Approved FDA decision Apr 29, 2025✓ Approved FDA decision Apr 2, 2025✓ Approved FDA decision Feb 7, 2025✓ Approved FDA decision See the full 2026 PDUFA calendar → This page aggregates ABBV's FDA catalysts from pdufa.bio's own calendar and decision archive. Each item links to its source page. Facts and dates only; verify against primary FDA / SEC / company filings.
Not affiliated with or endorsed by the FDA. pdufa.bio is an independent service; "FDA", "PDUFA", and all company, drug, and ticker names are used descriptively and remain the property of their owners. Informational and educational only — not investment advice. Data and historical statistics only; no trade recommendations and no individual-drug approval probabilities. Verify every date and outcome against primary FDA / SEC / company filings. © 2026 pdufa.bio